PDF herunterladen
Journal of Pediatric Biochemistry 2015; 05(04): 131-138
DOI: 10.1055/s-0036-1572525
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Neuroblastoma: Diagnostic and Clinical Aspects

Silvia Marino
1   Unit of Paediatric Haematology and Oncology, Department of Clinical and Experimental Medicine, Hospital Policlinico, University of Catania, Catania, Italy
,
Federica Puglisi
1   Unit of Paediatric Haematology and Oncology, Department of Clinical and Experimental Medicine, Hospital Policlinico, University of Catania, Catania, Italy
,
Gaetano Magro
2   Anatomic Pathology Section, Department of Medical, Surgical Sciences and Advanced Technologies “G.F. Ingrassia,” Hospital Policlinico, University of Catania, Catania, Italy
,
Giuseppe Belfiore
3   Unit of Radiology, Hospital Policlinico, University of Catania, Catania, Italy
,
Vincenzo Di Benedetto
4   Unit of Paediatric Surgery, Hospital Policlinico, University of Catania, Catania, Italy
,
Maria Grazia Scuderi
3   Unit of Radiology, Hospital Policlinico, University of Catania, Catania, Italy
,
Anna Portale
1   Unit of Paediatric Haematology and Oncology, Department of Clinical and Experimental Medicine, Hospital Policlinico, University of Catania, Catania, Italy
,
Salvatore D'Amico
1   Unit of Paediatric Haematology and Oncology, Department of Clinical and Experimental Medicine, Hospital Policlinico, University of Catania, Catania, Italy
,
Vito Miraglia
1   Unit of Paediatric Haematology and Oncology, Department of Clinical and Experimental Medicine, Hospital Policlinico, University of Catania, Catania, Italy
,
Maria Licciardello
1   Unit of Paediatric Haematology and Oncology, Department of Clinical and Experimental Medicine, Hospital Policlinico, University of Catania, Catania, Italy
,
Luca Lo Nigro
1   Unit of Paediatric Haematology and Oncology, Department of Clinical and Experimental Medicine, Hospital Policlinico, University of Catania, Catania, Italy
,
Milena La Spina
1   Unit of Paediatric Haematology and Oncology, Department of Clinical and Experimental Medicine, Hospital Policlinico, University of Catania, Catania, Italy
,
Giovanna Russo
1   Unit of Paediatric Haematology and Oncology, Department of Clinical and Experimental Medicine, Hospital Policlinico, University of Catania, Catania, Italy
,
Andrea Di Cataldo
1   Unit of Paediatric Haematology and Oncology, Department of Clinical and Experimental Medicine, Hospital Policlinico, University of Catania, Catania, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

21. Dezember 2015

30. Dezember 2015

Publikationsdatum:
13. Februar 2016 (online)

    Lizenzen und Reprints

Abstract

Due to its many clinical and biologic characteristics, neuroblastoma (NB) is a polyhedric neoplasm. It is a very complex, extremely heterogeneous disease that can regress spontaneously even without therapy. However, it frequently shows a very aggressive behavior, refractory to current intensive multimodal therapy. The tumor, originating from primordial neural crest cells, is biochemically unique for its metabolic pathways of catecholamine synthesis and metabolism. Homovanillic acid (HVA), the main metabolite of dopamine, and vanillylmandelic acid (VMA), the main metabolite of adrenalin and noradrenalin, are sensitive and convenient markers of NB since they are found in large amounts in patient's urine. The rate of NB patients with positive VMA and/or HVA at the diagnosis varies with the stage of the disease, with high-stage tumors being more likely to have abnormal levels. Other less specific NB tumor serum markers are neuron-specific enolase, ferritin, and lactate dehydrogenase. NB is one of the few pediatric tumors in which tumor markers have been shown to have a role in the diagnosis, prognosis, and disease monitoring.

Keywords

neuroblastoma - homovanillic acid - vanillylmandelic acid - neuron-specific enolase - ferritin - lactate dehydrogenase
 

  • References

  • 1 Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010; 24 (1) 65-86
    CrossrefPubMedGoogle Scholar
  • 2 Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3 (3) 203-216
    CrossrefPubMedGoogle Scholar
  • 3 Navarro S, Piqueras M, Villamón E , et al. New prognostic markers in neuroblastoma. Expert Opin Med Diagn 2012; 6 (6) 555-567
    CrossrefPubMedGoogle Scholar
  • 4 Virchow R. Hyperplasie der Zirbel und der Nebennieren. In: Die Krankhaften Geschwulste. Vol. 2. Berlin: Hirschwald; 1864
    Google Scholar
  • 5 Rothenberg AB, Berdon WE, D'Angio GJ, Yamashiro DJ, Cowles RA. Neuroblastoma-remembering the three physicians who described it a century ago: James Homer Wright, William Pepper, and Robert Hutchison. Pediatr Radiol 2009; 39 (2) 155-160
    CrossrefPubMedGoogle Scholar
  • 6 Hinterberger H, Bartholomew RJ. Catecholamines and their acidic metabolites in urine and in tumour tissue in neuroblastoma, ganglioneuroma and phaeochromocytoma. Clin Chim Acta 1969; 23 (1) 169-175
    CrossrefPubMedGoogle Scholar
  • 7 Bolkar ST, Ghadge MS, Raste AS. Biochemical parameters in neuroblastoma. Indian J Clin Biochem 2008; 23 (3) 293-295
    CrossrefPubMedGoogle Scholar
  • 8 Conte M, Parodi S, De Bernardi B , et al. Neuroblastoma in adolescents: the Italian experience. Cancer 2006; 106 (6) 1409-1417
    CrossrefPubMedGoogle Scholar
  • 9 Gigliotti AR, Di Cataldo A, Sorrentino S , et al. Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry. Eur J Cancer 2009; 45 (18) 3220-3227
    CrossrefPubMedGoogle Scholar
  • 10 Shimada H, Umehara S, Monobe Y , et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001; 92 (9) 2451-2461
    CrossrefPubMedGoogle Scholar
  • 11 Verloes A, Elmer C, Lacombe D , et al. Ondine-Hirschsprung syndrome (Haddad syndrome). Further delineation in two cases and review of the literature. Eur J Pediatr 1993; 152 (1) 75-77
    CrossrefPubMedGoogle Scholar
  • 12 Maris JM, Chatten J, Meadows AT, Biegel JA, Brodeur GM. Familial neuroblastoma: a three-generation pedigree and a further association with Hirschsprung disease. Med Pediatr Oncol 1997; 28 (1) 1-5
    CrossrefPubMedGoogle Scholar
  • 13 Maris JM, Brodeur GM. Genetics of neuroblastoma. In: Cowell JK, ed. Molecular Genetics of Cancer. 2nd ed. Oxford: BIOS; 2001: 335-361
    Google Scholar
  • 14 Origone P, Defferrari R, Mazzocco K, Lo Cunsolo C, De Bernardi B, Tonini GP. Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma. Am J Med Genet A 2003; 118A (4) 309-313
    CrossrefPubMedGoogle Scholar
  • 15 Martinsson T, Sjöberg RM, Hedborg F, Kogner P. Homozygous deletion of the neurofibromatosis-1 gene in the tumor of a patient with neuroblastoma. Cancer Genet Cytogenet 1997; 95 (2) 183-189
    CrossrefPubMedGoogle Scholar
  • 16 Satgé D, Moore SW, Stiller CA , et al. Abnormal constitutional karyotypes in patients with neuroblastoma: a report of four new cases and review of 47 others in the literature. Cancer Genet Cytogenet 2003; 147 (2) 89-98
    CrossrefPubMedGoogle Scholar
  • 17 Blatt J, Olshan AF, Lee PA, Ross JL. Neuroblastoma and related tumors in Turner's syndrome. J Pediatr 1997; 131 (5) 666-670
    CrossrefPubMedGoogle Scholar
  • 18 Satgé D, Sasco AJ, Carlsen NL , et al. A lack of neuroblastoma in Down syndrome: a study from 11 European countries. Cancer Res 1998; 58 (3) 448-452
    PubMedGoogle Scholar
  • 19 Schwab M, Alitalo K, Klempnauer KH , et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983; 305 (5931) 245-248
    CrossrefPubMedGoogle Scholar
  • 20 Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A 1984; 81 (15) 4940-4944
    CrossrefPubMedGoogle Scholar
  • 21 Katzenstein HM, Bowman LC, Brodeur GM , et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience—a pediatric oncology group study. J Clin Oncol 1998; 16 (6) 2007-2017
    CrossrefPubMedGoogle Scholar
  • 22 Canete A, Gerrard M, Rubie H , et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol 2009; 27 (7) 1014-1019
    CrossrefPubMedGoogle Scholar
  • 23 Rubie H, De Bernardi B, Gerrard M , et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol 2011; 29 (4) 449-455
    CrossrefPubMedGoogle Scholar
  • 24 De Bernardi B, Gerrard M, Boni L , et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009; 27 (7) 1034-1040
    CrossrefPubMedGoogle Scholar
  • 25 Nickerson HJ, Matthay KK, Seeger RC , et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 2000; 18 (3) 477-486
    CrossrefPubMedGoogle Scholar
  • 26 Rubie H, Hartmann O, Michon J , et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. J Clin Oncol 1997; 15 (3) 1171-1182
    PubMedGoogle Scholar
  • 27 Ozer E, Altungoz O, Unlu M, Aygun N, Tumer S, Olgun N. Association of MYCN amplification and 1p deletion in neuroblastomas with high tumor vascularity. Appl Immunohistochem Mol Morphol 2007; 15 (2) 181-186
    CrossrefPubMedGoogle Scholar
  • 28 Goto S, Umehara S, Gerbing RB , et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001; 92 (10) 2699-2708
    CrossrefPubMedGoogle Scholar
  • 29 Theissen J, Oberthuer A, Hombach A , et al. Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma. Genes Chromosomes Cancer 2014; 53 (8) 639-649
    CrossrefPubMedGoogle Scholar
  • 30 Cheung N-KV, Cohn SL. Neuroblastoma: Pediatric Oncology. Berlin: Springer; 2005
    Google Scholar
  • 31 Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997; 28 (4) 284-288
    CrossrefPubMedGoogle Scholar
  • 32 Rudnick E, Khakoo Y, Antunes NL , et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001; 36 (6) 612-622
    CrossrefPubMedGoogle Scholar
  • 33 Cooper R, Khakoo Y, Matthay KK , et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol 2001; 36 (6) 623-629
    CrossrefPubMedGoogle Scholar
  • 34 El Shafie M, Samuel D, Klippel CH, Robinson MG, Cullen BJ. Intractable diarrhea in children with VIP-secreting ganglioneuroblastomas. J Pediatr Surg 1983; 18 (1) 34-36
    CrossrefPubMedGoogle Scholar
  • 35 Lilling G, Wollman Y, Goldstein MN , et al. Inhibition of human neuroblastoma growth by a specific VIP antagonist. J Mol Neurosci 1994– 1995; 5 (4) 231-239
    PubMedGoogle Scholar
  • 36 Sendo D, Katsuura M, Akiba K , et al. Severe hypertension and cardiac failure associated with neuroblastoma: a case report. J Pediatr Surg 1996; 31 (12) 1688-1690
    CrossrefPubMedGoogle Scholar
  • 37 Chauty A, Raimondo G, Vergeron H , et al. Discovery of a neuroblastoma producing cardiogenic shock in a 2-month-old child [in French]. Arch Pediatr 2002; 9 (6) 602-605
    CrossrefPubMedGoogle Scholar
  • 38 Kwok SY, Cheng FW, Lo AF, Leung WK, Yam MC, Li CK. Variants of cardiomyopathy and hypertension in neuroblastoma. J Pediatr Hematol Oncol 2014; 36 (3) e158-e161
    CrossrefPubMedGoogle Scholar
  • 39 de Grauw AM, Mul D, van Noesel MM, Buddingh EP. Stress hyperglycaemia as a result of a catecholamine producing tumour in an infant. BMJ Case Rep 2015; . doi:10.1136/bcr-2014-209091
    PubMedGoogle Scholar
  • 40 Brodeur GM, Pritchard J, Berthold F , et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11 (8) 1466-1477
    CrossrefPubMedGoogle Scholar
  • 41 Pritchard J, Barnes J, Germond S , et al; European Neuroblastoma Study Group. Stage and urinary catecholamine metabolite excretion in neuroblastoma. Lancet 1989; 2 (8661) 514-515
    PubMedGoogle Scholar
  • 42 LaBrosse EH, Com-Nougué C, Zucker JM , et al. Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors. Cancer Res 1980; 40 (6) 1995-2001
    PubMedGoogle Scholar
  • 43 Monsaingeon M, Perel Y, Simonnet G, Corcuff JB. Comparative values of catecholamines and metabolites for the diagnosis of neuroblastoma. Eur J Pediatr 2003; 162 (6) 397-402
    PubMedGoogle Scholar
  • 44 Strenger V, Kerbl R, Dornbusch HJ , et al. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatr Blood Cancer 2007; 48 (5) 504-509
    CrossrefPubMedGoogle Scholar
  • 45 Davidson DF. Simultaneous assay for urinary 4-hydroxy-3-methoxy-mandelic acid, 5-hydroxyindoleacetic acid and homovanillic acid by isocratic HPLC with electrochemical detection. Ann Clin Biochem 1989; 26 (Pt 2) 137-143
    CrossrefPubMedGoogle Scholar
  • 46 Allenbrand R, Garg U. Quantitation of homovanillic acid (HVA) and vanillylmandelic acid (VMA) in urine using gas chromatography-mass spectrometry (GC/MS). Methods Mol Biol 2010; 603: 261-269
    PubMedGoogle Scholar
  • 47 Hsu WY, Chen CM, Tsai FJ, Lai CC. Simultaneous detection of diagnostic biomarkers of alkaptonuria, ornithine carbamoyltransferase deficiency, and neuroblastoma disease by high-performance liquid chromatography/tandem mass spectrometry. Clin Chim Acta 2013; 420: 140-145
    CrossrefPubMedGoogle Scholar
  • 48 Shi RZ, Ho YP, Yeung JH , et al. Development of an enzyme-linked immunosorbent assay with monoclonal antibody for quantification of homovanillic acid [corrected] in human urine samples. Clin Chem 1998; 44 (8, Pt 1) 1674-1679
    PubMedGoogle Scholar
  • 49 Tuchman M, Robison LL, Maynard RC, Ramnaraine ML, Krivit W. Assessment of the diurnal variations in urinary homovanillic and vanillylmandelic acid excretion for the diagnosis and follow-up of patients with neuroblastoma. Clin Biochem 1985; 18 (3) 176-179
    CrossrefPubMedGoogle Scholar
  • 50 Gregianin LJ, McGill AC, Pinheiro CM, Brunetto AL. Vanilmandelic acid and homovanillic acid levels in patients with neural crest tumor: 24-hour urine collection versus random sample. Pediatr Hematol Oncol 1997; 14 (3) 259-265
    CrossrefPubMedGoogle Scholar
  • 51 Cangemi G, Barco S, Reggiardo G , et al. Interchangeability between 24-hour collection and single spot urines for vanillylmandelic and homovanillic acid levels in the diagnosis of neuroblastoma. Pediatr Blood Cancer 2013; 60 (12) E170-E172
    CrossrefPubMedGoogle Scholar
  • 52 Barco S, Gennai I, Reggiardo G , et al. Urinary homovanillic and vanillylmandelic acid in the diagnosis of neuroblastoma: report from the Italian Cooperative Group for Neuroblastoma. Clin Biochem 2014; 47 (9) 848-852
    CrossrefPubMedGoogle Scholar
  • 53 Di Cataldo A, Dau D, Conte M , et al; Italian Cooperative Group for Neuroblastoma. Diagnostic and prognostic markers in infants with disseminated neuroblastoma: a retrospective analysis from the Italian Cooperative Group for Neuroblastoma. Med Sci Monit 2009; 15 (1) MT11-MT18
    PubMedGoogle Scholar
  • 54 Hann HW, Bombardieri E, Serum markers and prognosis in neuroblastoma: Ferritin, LDH, NSE. In: Brodeur G, Sawada T, Tsuchida Y, Voute PA. eds. Neuroblastoma. Amsterdam: Elsevier; 2000: 371-381
    Google Scholar
  • 55 Simon T, Hero B, Hunneman DH, Berthold F. Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer 2003; 39 (13) 1899-1903
    CrossrefPubMedGoogle Scholar
  • 56 Zeltzer PM, Marangos PJ, Parma AM , et al. Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group. Lancet 1983; 2 (8346) 361-363
    PubMedGoogle Scholar
  • 57 Hann HW, Evans AE, Siegel SE , et al. Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res 1985; 45 (6) 2843-2848
    PubMedGoogle Scholar
  • 58 Berthold F, Kassenböhmer R, Zieschang J. Multivariate evaluation of prognostic factors in localized neuroblastoma. Am J Pediatr Hematol Oncol 1994; 16 (2) 107-115
    PubMedGoogle Scholar
  • 59 Berthold F, Trechow R, Utsch S, Zieschang J. Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases. Am J Pediatr Hematol Oncol 1992; 14 (3) 207-215
    CrossrefPubMedGoogle Scholar
  • 60 Shuster JJ, McWilliams NB, Castleberry R , et al. Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study. Am J Clin Oncol 1992; 15 (4) 295-303
    CrossrefPubMedGoogle Scholar
  • 61 Lau L. Neuroblastoma: a single institution's experience with 128 children and an evaluation of clinical and biological prognostic factors. Pediatr Hematol Oncol 2002; 19 (2) 79-89
    CrossrefPubMedGoogle Scholar
  • 62 Cangemi G, Reggiardo G, Barco S , et al. Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma. Onco Targets Ther 2012; 5: 417-423
    PubMedGoogle Scholar
  • 63 Geatti O, Shapiro B, Sisson JC , et al. Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: preliminary experience in ten cases. J Nucl Med 1985; 26 (7) 736-742
    PubMedGoogle Scholar
  • 64 Voute PA, Hoefnagel CA, Marcuse HR, de Kraker J. Detection of neuroblastoma with 131I-meta-iodobenzylguanidine. Prog Clin Biol Res 1985; 175: 389-398
    PubMedGoogle Scholar
  • 65 Kushner BH, Yeh SD, Kramer K, Larson SM, Cheung NK. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003; 21 (6) 1082-1086
    CrossrefPubMedGoogle Scholar
  • 66 Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001; 19 (14) 3397-3405
    PubMedGoogle Scholar
  • 67 Scanga DR, Martin WH, Delbeke D. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin Nucl Med 2004; 29 (2) 86-90
    CrossrefPubMedGoogle Scholar
  • 68 Monclair T, Brodeur GM, Ambros PF , et al; INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009; 27 (2) 298-303
    CrossrefPubMedGoogle Scholar
  • 69 Cecchetto G, Mosseri V, De Bernardi B , et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005; 23 (33) 8483-8489
    CrossrefPubMedGoogle Scholar
  • 70 Dubois SG, London WB, Zhang Y , et al. Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer 2008; 51 (5) 589-592
    CrossrefPubMedGoogle Scholar
  • 71 Mossé YP, Laudenslager M, Longo L , et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455 (7215) 930-935
    CrossrefPubMedGoogle Scholar
  • 72 Haupt R, Garaventa A, Gambini C , et al. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry. J Clin Oncol 2010; 28 (14) 2331-2338
    CrossrefPubMedGoogle Scholar